I did notice that and thought it’s part of the reason Nader wants all of those vials produced before approval and a single order.
The auditors could, under GAAP, assign that a value of $0. In essence, that is the street value. Who would buy it?
The financials are juiced for the time being but in the end, that asset is what the highest bidder will pay.
I don’t believe uplist is a possibility and is <10%. Nader just stringing that along and probably keeping it alive just enough to avoid having to 8k the denial.
It will be announced after the CD12 preliminary findings are announced. He always needs the rabbit for the dogs to chase... yet the dogs never catch the rabbit but keep running around the track putting miles on but going nowhere
Grip